Cytotoxic Properties of Immunoconjugates Containing Melittin-like Peptide 101 Against Prostate Cancer: in Vitro and in Vivo Studies

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2004 Jan 15

PMID 14722668

Citations 33

Authors

Pamela J Russell

Dean Hewish

Teresa Carter

Katy Sterling-Levis

Kim Ow

Meghan Hattarki

Larissa Doughty

Robin Guthrie

Deborah Shapira

Peter L Molloy

Jerome A Werkmeister

Alexander A Kortt

Affiliations

Soon will be listed here.

Abstract

Background: Monoclonal antibodies (MAbs) can target therapy to tumours while minimising normal tissue exposure. Efficacy of immunoconjugates containing peptide 101, designed around the first 22 amino acids of bee venom, melittin, to maintain the amphipathic helix, to enhance water solubility, and to increase hemolytic activity, was assessed in nude mice bearing subcutaneous human prostate cancer xenografts.

Methods: Mouse MAbs, J591 and BLCA-38, which recognise human prostate cancer cells, were cross-linked to peptide 101 using SPDP. Tumour-bearing mice were used to compare biodistributions of radiolabeled immunoconjugates and MAb, or received multiple sequential injections of immunoconjugates. Therapeutic efficacy was assessed by delay in tumour growth and increased mouse survival.

Results: Radiolabeled immunoconjugates and antibodies showed similar xenograft tropism. Systemic or intratumoural injection of immunoconjugates inhibited tumour growth in mice relative to carrier alone, unconjugated antibody and nonspecific antibody-peptide conjugates and improved survival for treated mice.

Conclusions: Immunoconjugates deliver beneficial effects; further peptide modifications may increase cytotoxicity.

Citing Articles

Bee Venom: Composition and Anticancer Properties.

Gajski G, Leonova E, Sjakste N Toxins (Basel). 2024; 16(3).

PMID: 38535786 PMC: 10975291. DOI: 10.3390/toxins16030117.

Hosts and Heterologous Expression Strategies of Recombinant Toxins for Therapeutic Purposes.

di Leandro L, Colasante M, Pitari G, Ippoliti R Toxins (Basel). 2023; 15(12).

PMID: 38133203 PMC: 10748335. DOI: 10.3390/toxins15120699.

Cationic Proteins Rich in Lysine Residue Trigger Formation of Non-bilayer Lipid Phases in Model and Biological Membranes: Biophysical Methods of Study.

Li M, Gasanoff E J Membr Biol. 2023; 256(4-6):373-391.

PMID: 37735238 DOI: 10.1007/s00232-023-00292-y.

Effective treatment of metastatic sentinel lymph nodes by dual-targeting melittin nanoparticles.

Dai Y, Yu X, Leng Y, Peng X, Wang J, Zhao Y J Nanobiotechnology. 2023; 21(1):245.

PMID: 37528426 PMC: 10391974. DOI: 10.1186/s12951-023-02026-7.

An Updated Review Summarizing the Anticancer Efficacy of Melittin from Bee Venom in Several Models of Human Cancers.

Pandey P, Khan F, Khan M, Kumar R, Upadhyay T Nutrients. 2023; 15(14).

PMID: 37513529 PMC: 10385528. DOI: 10.3390/nu15143111.

References

Li Y, Tian Z, Rizvi S, Bander N, Allen B . In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis. 2004; 5(1):36-46. DOI: 10.1038/sj.pcan.4500543. View

RIVETT D, Kirkpatrick A, Hewish D, Reilly W, Werkmeister J . Dimerization of truncated melittin analogues results in cytolytic peptides. Biochem J. 1996; 316 ( Pt 2):525-9. PMC: 1217380. DOI: 10.1042/bj3160525. View

Walker K, Russell P, Kingsley E, Philips J, Raghavan D . Detection of malignant cells in voided urine from patients with bladder cancer, a novel monoclonal assay. J Urol. 1989; 142(6):1578-83. DOI: 10.1016/s0022-5347(17)39172-3. View

Liu H, Rajasekaran A, Moy P, Xia Y, Kim S, Navarro V . Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 1998; 58(18):4055-60. View

Denardo S, Kroger L, Denardo G . A new era for radiolabeled antibodies in cancer?. Curr Opin Immunol. 1999; 11(5):563-9. DOI: 10.1016/s0952-7915(99)00017-5. View

Panchal R, Cusack E, Cheley S, Bayley H . Tumor protease-activated, pore-forming toxins from a combinatorial library. Nat Biotechnol. 1996; 14(7):852-6. DOI: 10.1038/nbt0796-852. View

Heston W . Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology. 1997; 49(3A Suppl):104-12. DOI: 10.1016/s0090-4295(97)00177-5. View

DUNN R, Weston K, Longhurst T, Lilley G, RIVETT D, Hudson P . Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin. Immunotechnology. 1996; 2(3):229-40. DOI: 10.1016/s1380-2933(96)00055-3. View

Russell P, Raghavan D, Gregory P, Philips J, Wills E, Jelbart M . Bladder cancer xenografts: a model of tumor cell heterogeneity. Cancer Res. 1986; 46(4 Pt 2):2035-40. View

10.

Werkmeister J, Kirkpatrick A, McKenzie J, RIVETT D . The effect of sequence variations and structure on the cytolytic activity of melittin peptides. Biochim Biophys Acta. 1993; 1157(1):50-4. DOI: 10.1016/0304-4165(93)90077-l. View

11.

Denmeade S, Nagy A, Gao J, Lilja H, Schally A, Isaacs J . Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res. 1998; 58(12):2537-40. View

12.

Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B . Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res. 1998; 58(6):1195-201. View

13.

Wright Jr G, Grob B, Haley C, Grossman K, Newhall K, Petrylak D . Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996; 48(2):326-34. DOI: 10.1016/s0090-4295(96)00184-7. View

14.

Grauer L, Lawler K, Marignac J, Kumar A, Goel A, Wolfert R . Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res. 1998; 58(21):4787-9. View

15.

Fletcher J, Jiang M . Possible mechanisms of action of cobra snake venom cardiotoxins and bee venom melittin. Toxicon. 1993; 31(6):669-95. DOI: 10.1016/0041-0101(93)90375-s. View

16.

Pettaway C, Pathak S, Greene G, Ramirez E, Wilson M, Killion J . Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res. 1996; 2(9):1627-36. View

17.

Elgamal A, Troychak M, Murphy G . ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate. 1998; 37(4):261-9. DOI: 10.1002/(sici)1097-0045(19981201)37:4<261::aid-pros8>3.0.co;2-#. View

18.

Rosenthal S, Haseman M, Polascik T . Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol. 2001; 7(1):27-37. View

19.

Habermann E, Jentsch J . [Sequence analysis of melittin from tryptic and peptic degradation products]. Hoppe Seylers Z Physiol Chem. 1967; 348(1):37-50. View

20.

Bostwick D, Pacelli A, Blute M, Roche P, Murphy G . Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998; 82(11):2256-61. DOI: 10.1002/(sici)1097-0142(19980601)82:11<2256::aid-cncr22>3.0.co;2-s. View